Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

148.64 -1.28 (-0.85%)
Streaming Delayed Price Updated: 12:14 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical,
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
From Johnson & Johnson
Via Business Wire
3 Stocks Mega Investors Are Buying
Three stocks became top choices for some of Wall Street's biggest investors. Each carrying their own merit, they all offer double-digit upside 
Via MarketBeat
Topics Regulatory Compliance
Exposures Legal Regulatory
Bev Jennings selected as VIP Speaker at Global Women Thrive Summit 2024
The presentation is virtual and live in-person as part of a collaboration with the WBENC Amplify Conference in Denver, COJACKSONVILLE, Fla. & DENVER - March 16, 2024 - PRLog -- Bev Jennings, a VIP... 
Via PRLog
Topics Supply Chain
Exposures Supply Chain
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
From Johnson & Johnson
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
From Brodsky & Smith LLC
Via GlobeNewswire
MarketBeat Week in Review – 4/15 - 4/19
The markets continued to move lower ahead of a big earnings week as analysts adjust valuations on the outlook for interest rates and geopolitical concerns 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Johnson & Johnson's Q1 2024 earnings offer a mixed picture of resilience amidst economic headwinds and provide insight into the broader medtech sector's health. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Supply Chain
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson is as Cheap as it’s Going to Get
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN)
From Brodsky & Smith LLC
Via GlobeNewswire
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population 
Via MarketBeat
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%
From Johnson & Johnson
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. (Nasdaq – SWAV), Apartment Income REIT Corp. (NYSE - AIRC), Model N, Inc. (NYSE – MODN), ARCA biopharma, Inc. (Nasdaq - ABIO)
From Brodsky & Smith LLC
Via GlobeNewswire
MarketBeat Week in Review – 4/8 - 4/12
The latest inflation readings moved stocks lower as investors reconsidered what higher-for-longer interest rates mean for corporate earnings and stock valuation 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend 
Via MarketBeat
Johnson & Johnson to Acquire Shockwave Medical
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the BofA Securities Health Care Conference
From Johnson & Johnson
Via Business Wire
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Completes Acquisition of Ambrx
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
From Johnson & Johnson
Via Business Wire
Verizon, Walgreens, 3M: 3 high-yield Dow stocks to buy now?
Dow's high-yielding trio, Verizon, Walgreens, and 3M face challenges, which are reflected in their stock-price declines. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Johnson & Johnson
Via Business Wire
4 med tech stocks with improving prognosis for 2024
MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.